

Regulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1

Gregg L. Semenza

Vascular Program, Institute for Cell Engineering, McKusick-Nathans Institute of Genetic Medicine, and Departments of Pediatrics, Medicine, Oncology, and Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
gsemenza@jhmi.edu

Metazoan organisms are dependent on a continuous supply of O₂ for survival. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that regulates oxygen homeostasis and plays key roles in development, physiology, and disease. HIF-1 activity is induced in response to continuous hypoxia, intermittent hypoxia, growth factor stimulation, and Ca²⁺ signaling. HIF-1 mediates adaptive responses to hypoxia, including erythropoiesis, angiogenesis, and metabolic reprogramming. In each case, HIF-1 regulates the expression of multiple genes encoding key components of the response pathway. HIF-1 also mediates maladaptive responses to chronic continuous and intermittent hypoxia, which underlie the development of pulmonary and systemic hypertension, respectively.

The complexity of metazoan life is sustained by energy generated through the oxidative metabolism of glucose and fatty acids in the mitochondria, which results in the production of reducing equivalents that are used to maintain an electrochemical gradient that drives ATP synthesis. This highly efficient mechanism for producing ATP is dependent on the utilization of O₂ as the terminal electron acceptor at complex IV of the respiratory chain. When electrons react with O₂ prematurely (e.g., at complex III), reactive oxygen species (ROS) are generated. Tonic, low-level ROS production represents a signal that mitochondrial function is intact, whereas increased ROS production, resulting from reduced or fluctuating O₂ availability, is a danger signal that the cell is at risk of oxidative damage and, if uncorrected, death. Our understanding of the mechanisms by which cells and organisms sense hypoxia have dramatically advanced over the last two decades, principally through the discovery of hypoxia-inducible factor 1 (HIF-1) and the delineation of its role as a master regulator of oxygen homeostasis. This paper will provide an update on advances that have occurred in the field of oxygen biology since it was last reviewed in the inaugural issue of *Physiology* (70).

Oxygen Sensing and Signal Transduction

Increased or decreased O₂ availability results in hyperoxia or hypoxia, respectively. Hyperoxia occurs physiologically as a result of excessive (“overshoot”) angiogenesis (80) and clinically when O₂ is delivered to patients at inappropriately high concentrations. Hypoxia is a fundamental physiological stimulus that occurs in response to tissue growth during normal development (11, 38, 80, 91, 92) and in disease states, such as anemia, hemorrhage, and pneumonia, that have afflicted humans and their ancestors throughout

time and therefore have exerted selective pressure for the evolution of adaptive responses. In addition, modern man is afflicted by novel scourges associated with living long and/or unwisely, such as tobacco-related lung disease, atherosclerotic cardiovascular disease, and cancer, that have not exerted selective pressure due to their late onset, both with respect to reproduction of the individual and evolution of the species. Hypoxia can occur continuously or intermittently and be either acute or chronic in duration. Whereas chronic continuous hypoxia may occur either in a physiological or pathological context, chronic intermittent hypoxia only occurs in a pathological context. The distinction between physiological and pathological responses to hypoxia is important and will be delineated in greater detail below.

Continuous hypoxia

HIF-1 is a heterodimeric protein that is composed of a constitutively expressed HIF-1 β subunit and an O₂-regulated HIF-1 α subunit (88). Under normoxic conditions, the HIF-1 α subunit is synthesized and subjected to hydroxylation on proline residue 402 and/or 564 by prolyl hydroxylase domain (PHD) proteins (principally PHD2) that use O₂ and α -ketoglutarate as substrates (FIGURE 1A) to catalyze a dioxygenase reaction in which one oxygen atom is inserted into the proline residue and the other oxygen atom is inserted into α -ketoglutarate to form succinate and CO₂ (12, 30). The protein OS-9 binds to both PHD2 and HIF-1 α , thereby facilitating hydroxylation (4). Prolyl hydroxylation is required for the binding of the von Hippel-Lindau protein (VHL), which interacts with Elongin C and thereby recruits a ubiquitin ligase complex (30, 31). The protein SSAT2, which interacts with HIF-1 α , VHL, and Elongin C, stabilizes the interaction of VHL with Elongin C, thereby facilitating ubiquitination of HIF-1 α (2). Ubiquitination marks

HIF-1 α for degradation by the proteasome (68). FIH-1 binds to HIF-1 α and negatively regulates transactivation function (49) by hydroxylating asparagine residue 803, which blocks the interaction of the HIF-1 α transactivation domain with the co-activator p300 or CBP (41). Thus both the stability and transcriptional activity of HIF-1 are negatively regulated by O₂-dependent hydroxylation (FIGURE 1A).

When cells are acutely subjected to hypoxia, the hydroxylation reactions are inhibited as a result of substrate (O₂) deprivation and/or increased mitochondrial production of ROS, which may inhibit the hydroxylases by oxidizing a ferrous ion in the catalytic site (24, 30). The loss of hydroxylase activity increases HIF-1 α stability and transactivation function, leading to its dimerization with HIF-1 β , binding of HIF-1 to its recognition sequence 5'-(A/G)CGTG-3' (71) in target genes, and increased transcription of target gene sequences into mRNA.

Intermittent hypoxia

Brief episodes of hypoxia and reoxygenation (intermittent hypoxia) are known to occur during swimming as a consequence of apneas triggered by the naso-pharyngeal reflex (60). Of greater concern is the chronic intermittent hypoxia that occurs as a result of obstructive sleep apnea and causes cardiovascular disease (34), as will be discussed below. Despite the fact that intermittent hypoxia involves short (15–30 s) episodes of hypoxia followed by longer (e.g., 5 min) periods of reoxygenation, HIF-1 activity is induced, albeit by mechanisms that are distinct from those regulating its activity under conditions of chronic hypoxia (96).

The signal transduction pathways by which intermittent hypoxia activates HIF-1 have been delineated in the PC12 rat pheochromocytoma cell line, in which hypoxia was previously (13) shown to induce membrane depolarization and increased intracellular Ca²⁺ ([Ca²⁺]_i). When these cells were exposed to 60 cycles of




FIGURE 1. Oxygen-dependent regulation of HIF-1 activity

A: the structural domains of HIF-1 α are shown. The basic helix-loop-helix (bHLH) and Per-ARNT-Sim homology (PAS) domains mediate dimerization with HIF-1 β (ARNT) and DNA binding; the oxygen-dependent degradation domain (ODD) encompasses the sites of prolyl hydroxylation (POH) that are required for VHL binding; and the transactivation domain (TAD) encompasses the site of asparaginyl hydroxylation (NOH) that blocks binding of the coactivators p300 and CBP. The prolyl (PHD2) and asparaginyl (FIH-1) hydroxylases utilize O₂ and α -ketoglutarate (α -KG) as substrates. Protein-protein interactions are indicated by double-sided arrows. B: the signal transduction pathways by which intermittent hypoxia induces HIF-1 α protein synthesis (red), protein stability (green), and transactivation (blue) are shown.

1.5% O₂ for 30 s followed by 20% O₂ for 5 min, HIF-1 α protein and HIF-1 transcriptional activity were induced and increased further after 120 cycles (95). In these cells, intermittent hypoxia triggered NADPH oxidase-dependent ROS production, which induced phospholipase C γ activity, leading to the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (FIGURE 1B). Binding of IP3 to its cognate receptor led to mobilization of intracellular Ca²⁺, which activated calcium-calmodulin kinase (CamK) and, together with diacylglycerol, induced protein kinase C (PKC) activity. PKC stimulated mTOR-dependent HIF-1 α synthesis and inhibited PHD2-dependent degradation of HIF-1 α (96). CamK phosphorylated the coactivator p300, thereby promoting its interaction with HIF-1 α , leading to transcriptional activation (95). In contrast to continuous hypoxia, in which HIF-1 α is rapidly degraded ($t_{1/2}$ < 5 min) on reoxygenation (88), HIF-1 α levels remain persistently elevated following intermittent hypoxia due to the persistent activation of mTOR (96), a finding that has significance in the context of

obstructive sleep apnea, in which pathological cardiovascular and respiratory responses persist for hours after the termination of intermittent hypoxia (63).

Oxygen-Independent Mechanisms for Regulating HIF-1

In addition to the O₂-dependent pathways described above, O₂-independent pathways regulating the synthesis and the degradation of HIF-1 α have been delineated. These pathways appear to be particularly important in the context of cancer.

Regulation of HIF-1 α degradation

Although the PHD2-VHL pathway is the critical mechanism regulating HIF-1 α stability in response to changes in O₂ concentration (FIGURE 1A), recent studies have revealed that the RACK1 protein can bind to HIF-1 α and interact with Elongin C, thereby recruiting an E3 ubiquitin-protein ligase complex (46). RACK1 can substitute for VHL to promote ubiquitination and




FIGURE 2. Oxygen-independent regulation of HIF-1 α protein levels

A: the regulation of HIF-1 α protein stability by RACK1 is shown. RACK1 binding is increased by treatment with the heat shock protein 90 (HSP90) inhibitor 17-allylaminogeldanamycin (17-AAG) or by the calcineurin inhibitor cyclosporine A (CsA). Binding of Ca²⁺ to calmodulin (Cam) activates calcineurin phosphatase activity, which inhibits RACK1 dimerization. B: the regulation of HIF-1 α protein synthesis by the PI3K-AKT-mTOR (purple) and MAP kinase (orange) pathways, which mediate phosphorylation of key regulators of translation (red), is shown. Arrow and blocked arrow indicate activation and inhibition, respectively.

degradation of HIF-1 α (FIGURE 2A), with the critical distinction that RACK1-HIF-1 α interaction is not O₂-regulated. Although RACK1 was originally identified as a protein that stabilized interactions between PKC and its substrates, PKC activity is not required for RACK1-mediated ubiquitination and degradation of HIF-1 α (46).

RACK1-mediated HIF-1 α degradation has been demonstrated in two contexts. First, heat shock protein 90 (HSP90) is known to bind to HIF-1 α , and HSP90 inhibitors have been shown to inhibit tumor growth and to induce proteasomal degradation of HIF-1 α even in cells lacking VHL (26). RACK1 was shown to compete with HSP90 for binding to the PAS-A subdomain of HIF-1 α (46). Treatment with an HSP90 inhibitor such as 17-allylaminogeldanamycin results in unopposed RACK1 binding leading to increased ubiquitination and degradation of HIF-1 α . The ability of HSP90 inhibitors to induce HIF-1 α degradation is dependent on RACK1 expression (46). These studies have delineated a novel mechanism of action contributing to the anti-cancer effect of HSP90 inhibitors.

RACK1 also appears to contribute to the mechanism of action of another important drug, cyclosporine A, which is an immunosuppressant that prevents tissue rejection following transplantation by inhibiting calcineurin, a Ca²⁺/calmodulin-dependent serine/threonine protein phosphatase (44). Cyclosporine A has been shown to inhibit hypoxia-induced HIF-1 α expression (14, 37). RACK1 consists of seven copies of the tryptophan-aspartate-rich WD40 repeat domain and forms dimers through homotypic interactions between the fourth WD40 (WD4) repeat domain (84). HIF-1 α and Elongin C bind to the WD7 repeat domain on separate RACK1 monomers such that dimerization is required for RACK1 to recruit Elongin C to HIF-1 α (47). Phosphorylation of RACK1 promotes its dimerization, and the catalytic subunit of calcineurin binds to RACK1 and mediates its dephosphorylation, thereby inhibiting dimerization and RACK1-dependent HIF-1 α degradation (FIGURE 2A). Ionomycin, a calcium ionophore, was shown to increase HIF-1 α levels even in RCC4 cells, which lack functional VHL (47). Thus calcineurin activation represents another mechanism, in addition to those identified in the response to intermittent hypoxia (FIGURE 1B), by which calcium signaling can increase HIF-1 activity (FIGURE 2A).

SSAT1, which shares 46% amino acid identity with SSAT2, also binds to HIF-1 α and promotes its ubiquitination and degradation (3). However, in contrast to SSAT2, which stabilizes the interaction of VHL and Elongin C (FIGURE 1A) and thereby promotes O₂-dependent ubiquitination (2), SSAT1 acts by stabilizing the interaction of HIF-1 α with RACK1 (FIGURE 2A). Thus the paralogs SSAT1 and SSAT2 play complementary roles in promoting O₂-independent and O₂-dependent degradation of HIF-1 α , respectively.

Regulation of HIF-1 α synthesis

The principal mechanism for transducing extracellular signals to the nucleus is by the binding of growth factors, cytokines, and other ligands to cognate receptor tyrosine kinases and G-protein-coupled receptors on the cell surface, leading to the activation of the phosphatidylinositol-3-kinase (PI3K) and MAP kinase pathways (FIGURE 2B). Signal transduction through these pathways stimulates cell survival, growth, and proliferation. An inevitable consequence of cell growth and proliferation is increased O₂ consumption, so it is perhaps not surprising that these same signal transduction pathways induce what can be considered pre-emptive HIF-1 activity because it occurs in an O₂-independent manner (19, 42, 85, 98).

Treatment of MCF-7 human breast cancer cells with heregulin, which binds to heterodimers composed of the human epidermal growth factor receptor family members HER2 and HER3, activates PI3K, which phosphorylates the serine-threonine kinase AKT (protein kinase B). Activated AKT phosphorylates and activates the mammalian target of rapamycin (mTOR). Activated mTOR phosphorylates two key regulators of translation, p70 S6 kinase (p70^{S6K}) and eIF-4E binding protein 1 (4E-BP1). Activated p70^{S6K} phosphorylates ribosomal protein S6, whereas phosphorylation of 4E-BP1 blocks its ability to interact with and inhibit eIF-4E, a critical regulator of cap-dependent mRNA translation (FIGURE 2B), and these actions of mTOR increase the rate of translation of a subset of cellular mRNAs (25, 28). Heregulin treatment increases the synthesis of HIF-1 α protein in MCF-7 cells, and this effect is blocked by rapamycin, which is a specific inhibitor of mTOR activity (42). As in the case of HSP90 inhibitors (FIGURE 2A), rapamycin and its derivatives are a class of drugs currently in clinical trials as anti-cancer agents, and their anti-cancer effects are strongly associated with their inhibition of HIF-1 (50, 83).

HIF-1-Mediated Adaptive Responses to Hypoxia

HIF-1 mediates cell autonomous, tissue-restricted, and systemic homeostatic responses to hypoxia. An illustrative example of each of these is described below.

Erythropoiesis

Red blood cells function to deliver O₂ from the lungs to every cell in the body. Acute blood loss, ascent to high altitude, and pneumonia each results in a reduction in the blood O₂ content. The ensuing tissue hypoxia induces HIF-1 activity in cells throughout the body, including specialized cells in the kidney that produce erythropoietin (EPO), a glycoprotein hormone that is secreted into the blood and binds to its cognate receptor on erythroid progenitor cells, thereby stimulating their survival and differentiation (29). Analysis of the sequences regulating hypoxia-induced *EPO* gene

transcription led to the discovery of HIF-1 (72). Subsequently, HIF-1 has been shown to orchestrate erythropoiesis by coordinately regulating the expression of multiple genes encoding proteins responsible for the intestinal uptake, tissue recycling, and delivery of iron to the bone marrow for its use in the synthesis of hemoglobin (FIGURE 3A), including transferrin (66), transferrin receptor (48, 81), ceruloplasmin (53), and hepcidin (59). In addition, HIF-1 also activates transcription of the EPO receptor (51).

Erythropoiesis is impaired in *Hif1a*^{-/-} (homozygous HIF-1 α -null) embryos and the erythropoietic defects in HIF-1 α -deficient erythroid colonies could not be corrected by cytokines, such as vascular endothelial growth factor (VEGF) or EPO, but were ameliorated by administration of Fe-salicylaldehyde isonicotinoylhydrazone, a compound that can deliver iron into cells independently of iron transport proteins, which was consistent with reduced levels of transferrin receptor in HIF-1 α -deficient embryos and yolk sacs (93). In contrast, deficiency of HIF-2 α (which, like HIF-1 α , is O₂ regulated, dimerizes with HIF-1 β and activates target gene expression) has a major effect on EPO production in adult mice (23).

Angiogenesis

Erythropoiesis represents an adaptive response to systemic hypoxia. In contrast, angiogenesis represents a local tissue response to decreased oxygenation. As cells grow and proliferate, their consumption of O₂ increases and HIF-1 activity is induced, either as a result of preemptive growth factor-mediated induction (FIGURE 2B) or as a result of tissue hypoxia (FIGURE 1A). HIF-1 then coordinately activates the transcription of multiple genes encoding angiogenic growth factors and cytokines (FIGURE 3B), including vascular endothelial growth factor (VEGF), stromal-derived factor 1 (SDF-1), placental growth factor (PLGF), angiopoietin 1 and 2, and platelet-derived growth factor B (5, 8, 18, 32, 76), which bind to cognate receptors on vascular endothelial and smooth muscle cells as well as on endothelial

progenitor cells, mesenchymal stem cells, and other bone marrow-derived angiogenic cells (FIGURE 3B). In addition, HIF-1 regulates the expression of CXCR4 (79), which is the receptor for SDF-1, and VEGFR1 (22,




FIGURE 3. Adaptive responses to hypoxia

A: the regulation of erythropoiesis is shown. Direct HIF-1 target genes are indicated in blue. Arrow and blocked arrow indicate activation and repression, respectively. B: the regulation of angiogenesis is shown. Direct HIF-1 target genes are indicated in blue, whereas genes that may be either direct or indirect (secondary) targets of HIF-1 are indicated in maroon. The combination arrow/blocked arrows indicate that the genes encoding angiopoietin (ANGPT) 1 and 2 may be activated or repressed by HIF-1 in response to hypoxia depending on the cell type. C: the regulation of glucose and energy metabolism is shown. Green numerals indicate processes that are stimulated by HIF-1: 1) COX4-1 to COX4-2 subunit switch; 2) expression of glucose transporters GLUT1 and GLUT3; 3) expression of glycolytic enzymes; 4) expression of lactate dehydrogenase A; and 6) mitochondrial autophagy. Red numeral indicates process that is inhibited by HIF-1: 5) pyruvate dehydrogenase activity. AcCoA, acetyl coenzyme A; ETC, electron transport chain; TCA, tricarboxylic acid cycle.

Downloaded from <http://physiologyonline.physiology.org/> by 10.220.33.4 on November 25, 2017

55), which binds VEGF and PLGF. Thus, as described above for erythropoiesis, HIF-1 functions as a master regulator to control angiogenesis at multiple levels and vascularization fails in *Hif1a*^{-/-} (homozygous HIF-1 α -null) embryos (27, 67), whereas *Hif1a*^{+/-} (heterozygous HIF-1 α -null) adult mice have impaired vascularization following arterial occlusion (5).

Whereas the hypoxia-induced expression of HIF-1 provides a mechanism to ensure that every cell receives adequate perfusion in young and healthy animals, aging and diabetes impair angiogenesis (FIGURE 3B) by inhibiting the induction of HIF-1 (5, 9, 10, 45). Remarkably, this impairment of angiogenesis can be overcome by HIF-1 α gene therapy in ischemic muscle (5) and wound tissue (45) or by local administration of desferrioxamine, an iron chelator that inhibits the HIF-1 α hydroxylases, into ischemic skin (10).

“This remarkable finding indicates that HIF-1 regulates mitochondrial metabolism even in the tissue exposed to the highest Po₂ . . .”

Glucose and energy metabolism

Individual cells must adapt to O₂ deprivation by reprogramming their metabolism. The metabolic alterations that are induced by hypoxia are profound (FIGURE 3C). Perhaps the most subtle adaptation identified thus far is a subunit switch that occurs in cytochrome *c* oxidase (COX; complex IV), in which the COX4-1 regulatory subunit is replaced by the COX4-2 isoform as a result of HIF-1-mediated transcriptional activation of genes encoding COX4-2 and LON, a mitochondrial protease that is required for the hypoxia-induced degradation of COX4-1 (20). This subunit switch serves to optimize the efficiency with which COX transfers electrons to O₂ under hypoxic conditions. Remarkably, the budding yeast *Saccharomyces cerevisiae* also switches COX subunits in response to hypoxia (40) but does so by a completely different molecular mechanism since yeast do not have a HIF-1 homolog. The similar regulation of COX activity in yeast and human cells indicates that the selection for O₂-dependent homeostatic regulation of mitochondrial respiration is ancient and likely to be shared by all eukaryotic organisms (20).

A more drastic alteration is the shunting of pyruvate away from the mitochondria by the HIF-1-mediated activation of the *PDK1* gene encoding pyruvate dehydrogenase (PDH) kinase 1 (35, 56), which phosphorylates the catalytic subunit of PDH, the enzyme that converts pyruvate into acetyl coenzyme A (AcCoA) for entry into the mitochondrial tricyclic acid cycle (FIGURE 3C), which generates reducing equivalents that are donated to the electron transport chain. The reduced delivery of substrate to the mitochondria for oxidative phosphorylation results in reduced ATP syn-

thesis, which must be compensated for by increased glucose uptake via glucose transporters and increased conversion of glucose to lactate by the activity of glycolytic enzymes and lactate dehydrogenase A (FIGURE 3C), which are all encoded by HIF-1 target genes (27, 67, 69, 71).

Induction of PDK1 expression will inhibit the oxidative metabolism of AcCoA derived from glucose but will not affect the oxidative metabolism of AcCoA derived from fatty acids. The most draconian response to persistent hypoxia is the active destruction of mitochondria by selective mitochondrial autophagy (97). Remarkably, mouse embryo fibroblasts (MEFs) cultured at 1% O₂ reduce their mitochondrial mass by ~75% within 48 h through autophagy that is initiated by the HIF-1-dependent expression of BNIP3, a mitochondrial protein that competes with Beclin1 for binding to Bcl2, thereby freeing Beclin1 to trigger autophagy (97).

The adaptive significance of these metabolic responses to hypoxia were revealed by the finding that HIF-1 α -deficient MEFs die when cultured under hypoxic conditions for 72 h due to dramatically increased ROS levels (35, 69). The cells can be rescued by overexpression of PDK1 or BNIP3, or by treatment with free-radical scavengers (35, 69). It has long been known that mitochondrial ROS production increases under hyperoxic conditions (87). However, recent studies have demonstrated that acute hypoxia also leads to increased mitochondrial ROS production, which is required for the inhibition of HIF-1 α hydroxylase activity (24). Exposure of wild-type (WT) MEFs to hypoxia for 48 h results in reduced ROS levels, in contrast to *Hif1a*^{-/-} MEFs in which ROS levels are markedly increased (35, 97).

The following conclusions can be drawn regarding the metabolic adaptation to hypoxia. The increase in glycolysis and decrease in respiration that occur in response to hypoxia do not represent a passive effect of substrate (O₂) deprivation but instead represent an active response of the cell to counteract the reduced efficiency of respiration under hypoxic conditions, which in the absence of adaptation results in the accumulation of toxic levels of ROS. These studies indicate that a major role of HIF-1 is to establish, at any O₂ concentration, the optimal balance between glycolytic and oxidative metabolism that maximizes ATP production without increasing ROS levels. Finally, analysis of lung tissue from non-hypoxic *Hif1a*^{+/-} mice, which are heterozygous for a HIF-1 α -null allele and thus partially HIF-1 α deficient, revealed an ~50% decrease in mitochondrial mass compared with WT littermates (97). This remarkable finding indicates that HIF-1 regulates mitochondrial metabolism even in the tissue exposed to the highest Po₂, indicating that HIF-1 performs this critical function over the entire range of physiological Po₂. Thus HIF-1 maintains the metabolic/redox homeostasis that is essential for metazoan cells to live with O₂.

HIF-1-Mediated Pathological Responses to Hypoxia

Continuous hypoxia and pulmonary hypertension

The only organ to receive 100% of cardiac output is the lungs, which receive the blood that is pumped from the right ventricle. The pulmonary arterial circulation functions to load erythrocytes with O₂. Blood is then returned to the left heart from which it is pumped through the systemic circulation to all tissues of the body. Arterioles in the systemic circulation dilate in response to hypoxia, which is an autoregulatory device to maintain tissue oxygenation. In contrast, arterioles in the pulmonary circulation constrict in response to hypoxia to shunt blood away from lung tissue that is not oxygenated. Whereas this is an adaptive response in the setting of pneumonia, it is maladaptive in the setting of chronic lung disease, in which alveolar hypoxia is widespread. The right ventricle is forced to pump against greater resistance (pulmonary hypertension), resulting in ventricular hypertrophy and ultimately heart failure. HIF-1 plays a key role in this maladaptive response as determined in a mouse model in which animals are maintained in an ambient O₂ concentration of 10% for 3 wk (94).

HIF-1 mediates multiple pathogenic responses of pulmonary artery smooth muscle cells (PASMCs) to hypoxia. HIF-1 inhibits the expression of the voltage-gated potassium channels K_v2.1 and K_v1.5 (90) and activates expression of the TRPC1 and TRPC6 store-operated calcium channels (89). Increased [K⁺]_i and [Ca²⁺]_i trigger depolarization of PASMCs (74) and vessel constriction (FIGURE 4A). In addition, HIF-1 promotes the expression of endothelin-1, both in PASMCs and endothelial cells, leading to activation of endothelin receptors on PASMCs, which promotes further K_v channel downregulation and vasoconstriction (89). HIF-1 also induces expression of the sodium-hydrogen exchanger NHE1, which increases intracellular pH (73). Increased [H⁺]_i and [Ca²⁺]_i in PASMCs promote cell proliferation. Finally, HIF-1 induces PASMC hypertrophy through mechanisms that have yet to be delineated (74). The combination of PASMC hypertrophy, constriction, and proliferation causes the reduction in the luminal diameter of pulmonary arterioles that underlies pulmonary hypertension (FIGURE 4A).

Mice heterozygous for a knockout allele at the locus encoding HIF-1α (94) or HIF-2α (7) are resistant to the development of hypoxia-induced pulmonary hypertension that is observed in their WT littermates. Remarkably, individuals with Chuvash congenital polycythemia, who are homozygous for an arginine-to-tryptophan missense mutation at residue 200 in VHL that impairs its ability to bind to hydroxylated HIF-1α (1), have increased basal ventilation and pulmonary vascular tone, and augmented pulmonary vasoconstrictive and cardiorespiratory responses to

acute hypoxia (77). This phenotype is a striking complement to the impaired pulmonary vasoconstrictive and cardiorespiratory responses to chronic hypoxia that are observed in *Hif1α*^{-/-} mice (36, 94).

Chronic intermittent hypoxia and systemic hypertension

Whereas chronic continuous hypoxia induces pulmonary hypertension, chronic intermittent hypoxia (CIH) induces systemic hypertension. CIH occurs in individuals with obstructive sleep apnea (OSA), in which airway occlusion results in cessation of breathing leading to hypoxemia, which then arouses the individual to breathe. OSA may be a contributing factor in 30% of patients with essential hypertension (43). The carotid body is a small chemosensory organ located at the bifurcation of the internal and external carotid arteries that senses arterial PO₂. CIH induces signaling from the carotid body that activates the sym-




FIGURE 4. Maladaptive responses to hypoxia

A: the role of HIF-1 in the pathogenesis of pulmonary hypertension induced in response to chronic continuous hypoxia is shown. **B:** the role of HIF-1 in the pathogenesis of systemic hypertension induced in response to chronic intermittent hypoxia is shown. EDN1, endothelin 1; K_v1.5, voltage-gated potassium channel 1.5; NHE1, sodium-hydrogen exchanger 1; TRPC1, transient receptor potential protein C1.

pathetic nervous system, leading to increased catecholamine secretion, which increases arterial tone, leading to hypertension (43, 61). Exposure of *Hif1a*^{+/-} mice and their WT littermates to CIH for 10 days results in marked increases in systolic and diastolic blood pressures and a significant elevation in plasma norepinephrine concentration in the WT mice, whereas their *Hif1a*^{+/-} littermates are unaffected (58). Remarkably, the carotid bodies of *Hif1a*^{+/-} mice, although structurally and histologically normal, do not respond to hypoxia, although they respond normally to CO₂ and cyanide (36, 58).

CIH induces ROS production in rodents (62) and humans (16) and induces HIF-1 α expression (58). Administration of the superoxide scavenger manganese tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride to WT mice blocks CIH-induced ROS production (57), hypertension (39), and HIF-1 α induction (58). Remarkably, in *Hif1a*^{+/-} mice, there is a complete loss of CIH-induced HIF-1 α expression and ROS production (58). These results indicate that ROS production is required for HIF-1 α induction and that HIF-1 α induction is required for ROS production, suggesting a feed-forward mechanism in which ROS induces HIF-1 α , which induces more ROS, leading to higher HIF-1 α expression (FIGURE 4B).

In contrast to the physiological response to continuous hypoxia observed in MEFs described above, in which HIF-1 activity ameliorates increases in ROS levels, the pathological response to CIH is characterized by a HIF-1-dependent increase in ROS levels. OSA is a complication of obesity and, like other complications of obesity, has not been subject to evolutionary selection due to its recent origin. Thus, as in the case of hypoxic pulmonary hypertension, a nonphysiological stimulus (CIH) elicits a maladaptive response in which HIF-1 contributes to disease pathogenesis.

Summary and Perspective

This review has summarized a small sample of the tremendous progress that has been made recently in understanding the molecular physiology of oxygen homeostasis and how it is dysregulated in various disease processes. The interested reader is encouraged to consult the many recent reviews that discuss other important aspects of hypoxic adaptation, which are not covered here due to space limitations (6, 15, 17, 21, 33, 52, 54, 65, 75, 78, 82, 86, 99). Because metazoan life on earth is absolutely dependent on O₂, it should not come as a surprise that O₂ and its homeostatic regulation by HIF-1 play essential roles that broadly span the fields of physiology and medicine. Clinical trials of drugs that inhibit HIF-1 in cancer patients and of HIF-1 gene therapy in patients with peripheral arterial disease are underway (52, 64). Four years after the inaugural issue of *Physiology*, the grand challenges remain: to further advance our understanding of the

adaptive responses that have evolved to maintain oxygen homeostasis as well as the maladaptive responses that result from unhealthy aspects of our life style, and to translate that understanding into the prevention and treatment of disease. ■

References

1. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT. Disruption of oxygen homeostasis underlies congenital *Chuvash polycythemia*. *Nat Genet* 32: 614–621, 2002.
2. Baek JH, Liu YV, McDonald KR, Wesley JB, Hubbi ME, Byun H, Semenza GL. Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1 α . *J Biol Chem* 282: 23572–23580, 2007.
3. Baek JH, Liu YV, McDonald KR, Wesley JB, Zhang H, Semenza GL. Spermidine/spermine-N1-acetyltransferase-1 binds to hypoxia-inducible factor-1 α (HIF-1 α) and RACK1 and promotes ubiquitination and degradation of HIF-1 α . *J Biol Chem* 282: 33358–33366, 2007.
4. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, Semenza GL. OS-9 interacts with hypoxia-inducible factor 1 α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1 α . *Mol Cell* 17: 503–512, 2005.
5. Bosch-Marcé M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, Shaked Y, Kerbel R, Lavalley T, Semenza GL. Effects of aging and hypoxia-inducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. *Circ Res* 101: 1310–1318, 2007.
6. Brahim-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. *J Mol Med* 85: 1301–1307, 2007.
7. Brusselmans K, Compennolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2 α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. *J Clin Invest* 111: 1519–1527, 2003.
8. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med* 10: 858–864, 2004.
9. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, Gurtner GC. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. *J Biol Chem* 283: 10930–10938, 2008.
10. Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, Aarabi S, Chan DA, Freedman ML, Giaccia AJ, Gurtner GC. Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1 α stabilization during ischemia. *Circulation* 116: 2818–2829, 2007.
11. Chen EY, Fujinaga M, Giaccia AJ. Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. *Teratology* 60: 215–225, 1999.
12. Chowdhury R, Hardy A, Schofield CJ. The human oxygen sensing machinery and its manipulation. *Chem Soc Rev* 37: 1308–1319, 2008.
13. Conforti L, Kobayashi S, Beitner-Johnson D, Conrad PW, Freeman T, Millhorn DE. Regulation of gene expression and secretory functions in oxygen-sensing pheochromocytoma cells. *Respir Physiol* 115: 249–260, 1999.
14. D'Angelo G, Duplan E, Vigne P, Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1 α Pro-564 hydroxylation. *J Biol Chem* 278: 15406–15411, 2003.
15. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. *Nat Rev Cancer* 8: 425–437, 2008.
16. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. *Am J Respir Crit Care Med* 165: 934–939, 2002.

17. Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. *Angiogenesis* 11: 121–140, 2008.
18. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 16: 4604–4613, 1996.
19. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. *J Biol Chem* 277: 38205–38211, 2002.
20. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. *Cell* 129: 111–122, 2007.
21. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. *Cell Cycle* 7: 1916–1924, 2008.
22. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. *J Biol Chem* 272: 23659–23667, 1997.
23. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of HIF-2 α results in anemia. *Proc Natl Acad Sci USA* 104: 2301–2306, 2007.
24. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. *Exp Physiol* 91: 807–819, 2006.
25. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes Dev* 18: 1926–1945, 2004.
26. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α -degradative pathway. *J Biol Chem* 277: 29936–29944, 2002.
27. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 α . *Genes Dev* 12: 149–162, 1998.
28. Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the “polypyrimidine tract” mRNA family. *Proc Natl Acad Sci USA* 91: 4441–4445, 1994.
29. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. *Methods Enzymol* 435: 179–197, 2007.
30. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell* 30: 393–402, 2008.
31. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF-1 α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. *Proc Natl Acad Sci USA* 97: 10430–10435, 2000.
32. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. *Circ Res* 93: 1074–1081, 2003.
33. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. *Biochem J* 414: 19–29, 2008.
34. Khayat R, Patt B, Hayes D Jr. Obstructive sleep apnea: the new cardiovascular disease. Part I: obstructive sleep apnea and the pathogenesis of vascular disease. *Heart Fail Rev*. In press.
35. Kim JW, Tchernyshov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab* 3: 177–185, 2006.
36. Kline DD, Peng YJ, Manalo DJ, Semenza GL, Prabhakar NR. Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 α . *Proc Natl Acad Sci USA* 99: 821–826, 2002.
37. Kong X, Lin Z, Caro J. Immunophilin-ligands FK506 and CsA inhibit HIF-1 α expression by a VHL- and ubiquitin-independent mechanism. *FEBS Lett* 580: 6182–6186, 2006.
38. Krishnan J, Ahuja P, Bodenmann S, Knapik D, Perriard E, Krek W, Perriard JC. Essential role of developmentally activated hypoxia-inducible factor 1 α for cardiac morphogenesis and function. *Circ Res* 103: 1139–1146, 2008.
39. Kumar GK, Rai V, Sharma SD, Ramakrishnan DP, Peng YJ, Souvannakitti D, Prabhakar NR. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress. *J Physiol* 575: 229–239, 2006.
40. Kwast KE, Burke PV, Poyton RO. Oxygen sensing and the transcriptional regulation of oxygen-responsive genes in yeast. *J Exp Biol* 201: 1177–1195, 1998.
41. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. *Genes Dev* 16: 1466–1471, 2002.
42. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. *Mol Cell Biol* 21: 3995–4004, 2001.
43. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia: influence of chemoreceptors and sympathetic nervous system. *J Hypertens* 15: 1593–1603, 1997.
44. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* 66: 807–815, 1991.
45. Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW. Age-dependent impairment of HIF-1 α expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. *J Cell Physiol* 217: 319–327, 2008.
46. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1 α and is required for O₂-independent and HSP90 inhibitor-induced degradation of HIF-1 α . *Mol Cell* 25: 207–217, 2007.
47. Liu YV, Hubbi ME, Pan F, McDonald KR, Mansharamani M, Cole RN, Liu JO, Semenza GL. Calcineurin promotes hypoxia-inducible factor 1 α expression by dephosphorylating RACK1 and blocking RACK1 dimerization. *J Biol Chem* 282: 37064–37073, 2007.
48. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. *J Biol Chem* 274: 24147–24152, 1999.
49. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1 α and VHL to mediate repression of HIF-1 transcriptional activity. *Genes Dev* 15: 2675–2686, 2001.
50. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* 10: 594–601, 2004.
51. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. *Blood* 105: 659–669, 2005.
52. Melillo G. Targeting hypoxia cell signaling for cancer therapy. *Cancer Metastasis Rev* 26: 341–352, 2007.
53. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor 1 in transcriptional activation of ceruloplasmin by iron deficiency. *J Biol Chem* 275: 21048–21054, 2000.
54. Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. *J Mol Med* 85: 1325–1330, 2007.
55. Okuyama H, Krishnamachary B, Zhou YF, Nagasawa H, Bosch-Marcé M, Semenza GL. Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. *J Biol Chem* 281: 15554–15563, 2006.
56. Papatreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab* 3: 187–197, 2006.
57. Peng YJ, Overholt JL, Kline D, Kumar GK, Prabhakar NR. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. *Proc Natl Acad Sci USA* 100: 10073–10078, 2003.
58. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marcé M, Kumar GK, Semenza GL, Prabhakar NR. Heterozygous HIF-1 α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. *J Physiol* 577: 705–716, 2006.
59. Peyssonnaud C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). *J Clin Invest* 117: 1926–1932, 2007.
60. Prabhakar NR. Novel role for reactive oxygen species as amplifiers of intermittent hypoxia. *J Neurophysiol* 97: 1877, 2007.
61. Prabhakar NR, Dick TE, Nanduri J, Kumar GK. Systemic, cellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chronic intermittent hypoxia. *Exp Physiol* 92: 39–44, 2007.
62. Prabhakar NR, Kumar GK, Nanduri J, Semenza GL. ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. *Antioxid Redox Signal* 9: 1397–1403, 2007.
63. Prabhakar NR, Peng YJ, Jacono FJ, Kumar GK, Dick TE. Cardiovascular alterations by chronic intermittent hypoxia: importance of carotid body chemoreflexes. *Clin Exp Pharmacol Physiol* 32: 447–449, 2005.
64. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N. Use of a constitutively active hypoxia-inducible factor-1 α transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. *Circulation* 115: 1234–1243, 2007.
65. Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haske-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S, Sen CK, Gazaryan I, Cho S, Fink M, LaManna J. Harnessing hypoxic adaptation to prevent, treat, and repair stroke. *J Mol Med* 85: 1331–1338, 2007.
66. Rols A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. *J Biol Chem* 272: 20055–20062, 1997.

67. Ryan HE, Lo J, Johnson RS. HIF-1 α is required for solid tumor formation and embryonic vascularization. *EMBO J* 17: 3005–3015, 1998.
68. Salceda S, Caro J. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem* 272: 22642–22647, 1997.
69. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. *Mol Cell Biol* 21: 3436–3444, 2001.
70. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. *Physiology* 19: 176–182, 2004.
71. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. *J Biol Chem* 271: 32529–32537, 1996.
72. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol* 12: 5447–5454, 1992.
73. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL. HIF-1 regulates hypoxic induction of NHE1 expression and alkalization of intracellular pH in pulmonary arterial myocytes. *Am J Physiol Lung Cell Mol Physiol* 291: L941–L949, 2006.
74. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1 α deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. *Am J Physiol Lung Cell Mol Physiol* 281: L202–L208, 2001.
75. Shohet RV, Garcia JA. Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. *J Mol Med* 85: 1309–1315, 2007.
76. Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. *J Cell Physiol* 217: 809–818, 2008.
77. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, Robbins PA. Mutation of von Hippel-Lindau tumor suppressor and human cardiopulmonary physiology. *PLoS Med* 3: e290, 2006.
78. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. *Br J Haematol* 141: 325–334, 2008.
79. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 down-regulated by von Hippel-Lindau tumour suppressor pVHL. *Nature* 425: 307–311, 2003.
80. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. *J Neurosci* 15: 4738–4747, 1995.
81. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. *J Biol Chem* 274: 24142–24146, 1999.
82. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. *J Mol Med* 85: 1295–1300, 2007.
83. Thomas GV, Tran C, Mellinshoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. *Nat Med* 12: 122–127, 2006.
84. Thornton C, Tang KC, Phamluong K, Luong K, Vagts A, Nikanjam D, Yaka R, Ron D. Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization. *J Biol Chem* 279: 31357–31364, 2004.
85. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. *J Biol Chem* 277: 27975–27981, 2002.
86. Tuder RM, Yun JH, Bhunia A, Fijalkowska I. Hypoxia and chronic lung disease. *J Mol Med* 85: 1317–1324, 2007.
87. Turrens JF, Freeman BA, Levitt JG, Crapo JD. The effect of hyperoxia on superoxide production by lung submitochondrial particles. *Arch Biochem Biophys* 217: 401–410, 1982.
88. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci USA* 92: 5510–5514, 1995.
89. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia-inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca²⁺ in pulmonary arterial smooth muscle cells. *Circ Res* 98: 1528–1537, 2006.
90. Whitman EM, Pisarcik S, Luke T, Fallon M, Wang J, Sylvester JT, Semenza GL, Shimoda LA. Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K⁺ channel expression in pulmonary arterial myocytes. *Am J Physiol Lung Cell Mol Physiol* 294: L309–L318, 2008.
91. Wikenheiser J, Doughman YQ, Fisher SA, Watanabe M. Differential levels of tissue hypoxia in the developing chicken heart. *Dev Dyn* 235: 115–123, 2006.
92. Xu B, Doughman Y, Turakhia M, Jiang W, Landsettle CE, Agani FH, Semenza GL, Watanabe M, Yang YC. Partial rescue of defects in Cited2-deficient embryos by HIF-1 α heterozygosity. *Dev Biol* 301: 130–140, 2007.
93. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A, Prchal JT. Hypoxia-inducible factor 1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. *J Biol Chem* 281: 25703–25711, 2006.
94. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 α . *J Clin Invest* 103: 691–696, 1999.
95. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca²⁺/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. *J Biol Chem* 280: 4321–4328, 2005.
96. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1 α expression by intermittent hypoxia: involvement of NADPH oxidase, Ca²⁺ signaling, prolyl hydroxylases, and mTOR. *J Cell Physiol* 217: 674–685, 2008.
97. Zhang H, Bosch-Marcé M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. *J Biol Chem* 283: 10892–10903, 2008.
98. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1 α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res* 60: 1541–1545, 2000.
99. Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. *J Mol Med* 85: 1339–1346, 2007.